Study details
Enrolling now
CYTALUX (Pafolacianine) Trial
John Waters
NCT IDNCT07039526ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 2.4 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing a new drug called CYTALUX™ (pafolacianine) to help doctors see cancer cells during surgery. The goal is to determine if using CYTALUX™ with near-infrared fluorescent imaging improves the detection of malignant tissue in people undergoing surgical resection for cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CYTALUX™ (pafolacianine) injection preoperatively
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
pafolacianine
Drug routes
injection